Welcome to STN International Web Page URLs for STN Seminar Schedule - N. America NEWS "Ask CAS" for self-help around the clock NEWS May 12 EXTEND option available in structure searching NEWS 3 May 12 Polymer links for the POLYLINK command completed in REGISTRY NEWS New UPM (Update Code Maximum) field for more efficient patent NEWS May 27 SDIs in CAplus May 27 CAplus super roles and document types searchable in REGISTRY NEWS 6 Jun 28 Additional enzyme-catalyzed reactions added to CASREACT NEWS NEWS 8 Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R) NEWS 9 Jul 12 BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS NEWS 10 Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting IFIPAT/IFIUDB/IFICDB reloaded with new search and display AUG 02 NEWS 11 fields CAplus and CA patent records enhanced with European and Japan AUG 02 NEWS 12 Patent Office Classifications AUG 02 STN User Update to be held August 22 in conjunction with the NEWS 13 228th ACS National Meeting The Analysis Edition of STN Express with Discover! NEWS 14 AUG 02 (Version 7.01 for Windows) now available AUG 04 Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004 JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT NEWS EXPRESS MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004 STN Operating Hours Plus Help Desk Availability NEWS HOURS General Internet Information NEWS INTER Welcome Banner and News Items NEWS LOGIN NEWS PHONE Direct Dial and Telecommunication Network Access to STN CAS World Wide Web Site (general information) NEWS WWW

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:54:43 ON 09 AUG 2004

=> file reg COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
0.21 0.21

FULL ESTIMATED COST

h

FILE 'REGISTRY' ENTERED AT 10:54:48 ON 09 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 7 AUG 2004 HIGHEST RN 723734-66-5 DICTIONARY FILE UPDATES: 7 AUG 2004 HIGHEST RN 723734-66-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter <u>HELP PROP</u> at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

=> L1


STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS


L1 STR

AK1919N M2



Page 1-A

Cy @15



Page 1-B

VAR G1=18/19

VPA 14-1/3/4/5/6 S

VPA 15-10/11/12/13 S

NODE ATTRIBUTES:

HCOUNT IS M2 AT19 NSPEC IS R AT1 NSPEC IS R AT2 NSPEC IS R AT3 NSPEC IS R TANSPEC IS R AT NSPEC IS R ATNSPEC IS C 7 ATNSPEC IS C ATNSPEC IS R AT 9 NSPEC IS R 10 ATNSPEC IS R AT11 NSPEC IS R ΑT 12 NSPEC IS R AT13 NSPEC IS C AT14 NSPEC IS C AT15 NSPEC IS C AT 16 NSPEC IS C 17 ATDEFAULT MLEVEL IS ATOM

MLEVEL IS CLASS AT 7 14 16 17 18 19

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS

STEREO ATTRIBUTES: NONE

=> s l1

h

SAMPLE SEARCH INITIATED 10:57:09 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 1647 TO ITERATE

60.7% PROCESSED 1000 ITERATIONS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 30506 TO 35374

> eb c g cg b

2 ANSWERS

PROJECTED ANSWERS:

2 TO 173

L2

2 SEA SSS SAM L1

=> s 11 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END: y
FULL SEARCH INITIATED 10:57:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 32122 TO ITERATE

100.0% PROCESSED 32122 ITERATIONS

41 ANSWERS

SEARCH TIME: 00.00.01

тЗ

41 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY 156.68 SESSION 156.89

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 10:57:16 ON 09 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Aug 2004 VOL 141 ISS 7 FILE LAST UPDATED: 8 Aug 2004 (20040808/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.  $\begin{tabular}{ll} \end{tabular} \label{table_equation} \end{tabular}$ 

=> s 13

L4 .14 L3

=> s 14 and brown, d?/au 7837 BROWN, D?/AU

2 L4 AND BROWN, D?/AU

=> d 15, ibib abs fhitstr, 1-2

L5 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

Full
Text References

ACCESSION NUMBER:

2001:798214 HCAPLUS

DOCUMENT NUMBER:

135:344368

TITLE:

Process for the regioselective synthesis of 3,4-diaryl

substituted thiophenes

INVENTOR(S):

Brown, David L.; Ludwig, Cindy L.

PATENT ASSIGNEE(S):

Pharmacia Corporation, USA

SOURCE:

PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.					KIND DATE			APPLICATION NO.						D.	ATE		
	WO	2001	0813	33		A2	_	2001	1101		WO 2	001-	US13	092		2	0010	420
		$\mathtt{W}$ :	ΑE,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,
			HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	LS,
			LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PL,	PT,	RO,
			RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,
			VN,	YU,	ZA,	ZW,	AM,	AZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM			
		RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,
			DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,
			ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG		
	US	2002	1833	62		A1		2002	1205		US 2	001-	8394	24		2	0010	420
	ΕP	1276	736			A2		2003	0122		EP 2	001-	9287	81		2	0010	420
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
			IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	ΑL,	TR						
	US	6600	0 <u>52</u>			В1		2003									0010	420
	JP	2003	5312	02		Т2		2003	1021		JP 2	001-	5784	24		2	0010	420
	US	2003	2329	96		A1		2003	1218		US 2	003-	2585	07		2	0030	416
PRIO	RITY	APP	LN.	INFO	.:						US 2	000-	1995	33P		P 2	0000	425
	*										US 2	000-	2533	80P		P 2	0001	127
											WO 2	001-	US13	092	1	W 2	0010	420
OTHE:	R SO			CAS	REAC	т 13	5:34	4368	; MA	RPAT	135	:344	368					

A novel process for the regioselective prepn. of I, via the intermediates AΒ II and III using an alkali metal alkoxide ring cyclizing reagent where (R1 and R2 = substituted carbocycle or heterocycle; R3 = OR6 or NR7R8 and R6, R7 and R8 = H, (un)heterosubstituted hydrocarbyl; R4 and R5 are independently  ${\tt H}$  and optionally substituted alkyl), was accomplished. IV was prepd. in 66 % yield via the enamine intermediate of Me 3-[3-fluoro-4-(methylthio)phenyl]-4-phenyl-2-thiophenecarboxylate.

### IT 370874-59-2P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of 3,4-diarylthiophene)

370874-59-2 HCAPLUS RN

CN 2-Thiophenecarboxylic acid, 3-[4-(aminosulfonyl)-3-fluorophenyl]-4-phenyl-, methyl ester (9CI) (CA INDEX NAME)

ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

references Text

2001:798213 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):

135:344477

Preparation of 2-fluorobenzenesulfonyl-heterocycles

with COX-1 and COX-2 inhibiting activity for

pharmaceutical use in the treatment of inflammation Brown, David L.; Graneto, Matthew J.; Ludwig, Cindy

L.; Talley, John J.

PATENT ASSIGNEE(S):

SOURCE:

Pharmacia Corporation, USA

PCT Int. Appl., 242 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.					KIND DATE			APPLICATION NO.							ATE 	
	WO 200	10813	32														
	WO 200	10813	32		<b>A</b> 3		2002	0404									
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FΙ,	GB,	GD,	GE,	GH,	GM,
		HR,	ΗU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	LS,
		LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NO,	NZ,	PL,	PT,	RO,
		RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,
	*	VN,	YU,	ZA,	ZW,	AM,	AZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM			
	RW	: GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,
		ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG		
	US 200	21833	62		A1		2002	1205		US 2	001-	8394	24		2	0010	420
	EP 129	6971			A2 20030402				EP 2001-927279					2	0010	420	
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR						
	US 660	0052			В1		2003	0729		US 2	001-	8389	86		2	0010	420
	JP 200	35312	01		Т2		2003	1021		JP 2	001-	5784	23		2	0010	420
	US 2004092552															0030	711
PRIOR	RIORITY APPLN. INFO.:									US 2	000-	1995	33P		P 2	0000	425
										US 2	000-	2533	80P		P 2	0001	127
										WO 2	001-	US12	983	1	w 2	0010	420
OTHER	THER SOURCE(S):					MARPAT 135:344477											
~~																	

GI

h

AB 2-Fluorobenzenesulfonyl-heterocycles, such as I [A = 5 or 6 membered heterocycle or carbocycle, such as pyrazole, thiophene, isoxazole, furan; R1 = cyclohexyl, pyridinyl, Ph; R2 = Me, NH2; R3 = H, oxo, CN, halogen, alkyl, alkenyl, carboxyl, haloalkyl, heterocyclyl, cycloalkenyl, aminocarbonyl, etc.] with COX-1 and COX-2 inhibiting activity, were prepd. for therapeutic use as anti-inflammatory agents. Thus, pyrazole II was prepd. via a multistep synthetic sequence in which the last step was a a cyclocondensation reaction of 4-H2NSO2-3-F-C6H3NHNH2 and 3-Cl-4-Me-C6H3COCH2COCHF2 achieved by refluxing for 1 h. concd. HCl in EtOH to give II with 53% yield. The prepd. heterocycles were tested for COX-1 and -2 inhibiting activity.

IT 370874-28-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2-fluorobenzenesulfonyl-heterocycles with COX-1 and COX-2 inhibiting activity for pharmaceutical use in the treatment of inflammation)

RN 370874-28-5 HCAPLUS

CN Benzenesulfonamide, 2-fluoro-4-(4-phenyl-3-thienyl)- (9CI) (CA INDEX NAME)

=> d his

L1

(FILE 'HOME' ENTERED AT 10:54:43 ON 09 AUG 2004)

FILE 'REGISTRY' ENTERED AT 10:54:48 ON 09 AUG 2004

STRUCTURE UPLOADED

L2 2 S L1

L3 41 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 10:57:16 ON 09 AUG 2004

L4 14 S L3

L5 2 S L4 AND BROWN, D?/AU

=> s 14 not 15

```
=> s 16 and graneto, m?/au
            40 GRANETO, M?/AU
L7
             0 L6 AND GRANETO, M?/AU
=> s 16 and ludwig, c?/au
           270 LUDWIG, C?/AU
             0 L6 AND LUDWIG, C?/AU
^{\rm L8}
=> d 16, ibib abs fhitstr, 1-12
     ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
            ₩IAW N
   l ext
          ACCESSION NUMBER:
                         2004:565073 HCAPLUS
                         Use of cathepsin k inhibitors for the treatment of
TITLE:
                         glaucoma
INVENTOR(S):
                         Shepard, Allan; Clark, Abbot F.; Jacobson, Nasreen
                         Alcon, Inc., Switz.
PATENT ASSIGNEE(S):
SOURCE:
                         PCT Int. Appl., 57 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:
                         Patent
                         English
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                         KIND
                                DATE
                                            APPLICATION NO.
                                                                    DATE
     -------
                         ____
                                             _____
     WO 2004058238
                          A1
                                20040715
                                            WO 2003-US40511
                                                                    20031219
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM,
             AZ, BY, KG, KZ
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
             BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
             MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
             GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                             US 2002-436126P
                                                                 P 20021223
     Compns. contg. inhibitors of cathepsin K (CTSK) expression and/or activity
     are provided. Methods for the treatment of glaucoma using the compns. of
     the invention are further provided. The cathepsin K antagonist is
     selected from, but not limited to, the group consisting of monensin,
     brefeldin A, tunicamycin and 1,3-bis(acylamino)-2-propanone derivs.,
     cycloaltilisin 6, cycloaltilisin 7, AC-3-1, AC-3-3, AC-5-1,
     haploscleridamine, SB-331750, SB-357114, peptidomimetic aminomethyl
     ketones, \alpha, \alpha'-diacylamino ketones, alkoxymethyl ketones,
     cyanamides, pyridoxal propionate derivs. (including Clik-164 and
     Clik-166), SB-290190, \alpha-alkoxy ketone derivs., cyanamide derivs.,
     and N\alpha-acyl-\alpha-amino acid-(arylaminoethyl)amides.
IT 190658-17-4
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (use of cathepsin k inhibitors for treatment of glaucoma)
RN
     190658-17-4 HCAPLUS
CN
     4-Thiazolecarboxylic acid, 2-[3-[[(4-chlorophenyl)sulfonyl]methyl]-2-
```

L6

12 L4 NOT L5

thienyl]-, 2-[(2S)-4-methyl-1-oxo-2-[[(4-pyridinylmethoxy)carbonyl]amino]p entyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

L6 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2004:515493 HCAPLUS

DOCUMENT NUMBER:

141:71565

TITLE:

Preparation of pyrazines and related compounds as glucokinase activators for the treatment of type II

diabetes

INVENTOR(S):

Chen, Shaoqing; Corbett, Wendy Lea; Guertin, Kevin Richard; Haynes, Nancy-Ellen; Kester, Robert Francis; Mennona, Francis A.; Mischke, Steven Gregory; Qian, Yimin; Sarabu, Ramakanth; Scott, Nathan Robert;

Thakkar, Kshitij Chhabilbhai F. Hoffmann-La Roche Ag, Switz.

PATENT ASSIGNEE(S):

PCT Int. Appl., 243 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	PATENT NO.			KIND DATE			APPLICATION NO.						D	ATE			
WO	2004	0528	69		A1		2004	0624	]	WO 2	003-	EP14	0 <u>55</u>		2	0031	211
	w:	ΑE,	AG,	ΑĿ,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,	GE,
		GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,
		LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NI,	NO,	NZ,
		OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	ТJ,	TM,
		TN,	TR,	TT,	TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW,	AM,	ΑZ,	BY,
		KG,	ΚZ,	MD,	RU												
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,
		BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	ΙT,	LU,
		MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,
		GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG								
US	US 2004147748				A1		2004	0729	9 US 2003-732838						2	0031	210
PRIORIT	PRIORITY APPLN. INFO.:									US 2	002-	4328	06P		P 2	0021	212
									į	US 2	003-	5245	31P	,	P 2	0031	124

GI

h

$$0 = \begin{cases} R3 \\ 0 \\ R1 \end{cases} R^2$$

$$R^3$$

$$R^4$$

$$R^4$$

AB Title compd. I [R1 = alkyl; R2 = H, halo, nitro, etc.; R3 = cycloalkyl; R4 = SO2NR5R6, NHSO2CH3, [CH2]mNMe2, etc.; R5 = H, alkyl; R6 = alkyl; Y = CH, N; \* denotes an asym. carbon] and their pharmaceutically acceptable salts were prepd. For example, the Pd-catalyzed coupling of 2-amino-5-bromopyrazine with NaSMe, followed by reaction with (2R)-(3-chloro-4-metnanesufonylphenyl)-3-cyclopentylpropionic acid afforded compd. (R)-I [R1 = Me; R2 = Cl; R3 = cyclopetyl; R4 = SMe; Y = N] in 22.1% overall yield. In glucokinase activity assays (in vitro) using glucose-6-phosphate dehydrogenase (G6PDH), compds. I exhibited SC1.5 values less than or equal to 100 μM. Formulations are given. Compds. I are claimed useful for the treatment and prophylaxis of II type diabetes.

# IT 710321-98-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrazines and related compds. as glucokinase activators for the treatment of type II diabetes)

RN 710321-98-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



L6 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text

ACCESSION NUMBER: DOCUMENT NUMBER: TITLE: 2002:145039 HCAPLUS

136:325469

4-(4-Cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as Selective Cyclooxygenase-2 Inhibitors: Enhancement of the Selectivity by Introduction of a Fluorine Atom and Identification of a Potent, Highly Selective, and Orally Active COX-2 Inhibitor JTE-522

AUTHOR(S): Hashimoto, Hiromasa; Imamura, Katsuaki; Haruta,

Jun-ichi; Wakitani, Korekiyo

CORPORATE SOURCE: Central Pharmaceutical Research Institute, JT Inc.,

Takatsuki, Osaka, 569-1125, Japan

SOURCE: Journal of Medicinal Chemistry (2002), 45(7),

1511-1517

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

Ι

DOCUMENT TYPE: Journal LANGUAGE: English

LANGUAGE: English

Me S0 2NH 2

AB A series of 4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamide derivs., e.g., I, were synthesized and evaluated for their abilities to inhibit cyclooxygenase-2 (COX-2) and cyclooxygenase-1 (COX-1) enzymes. In this series, substituent effects at the ortho position to the sulfonamide group on the Ph ring were examd. Most substituents reduced or lost both COX-2 and COX-1 activities. In contrast, introduction of a fluorine atom preserved COX-2 potency and notably increased COX1/COX-2 selectivity. This work led to the identification of a potent, highly selective, and orally active COX-2 inhibitor I (JTE-522), which is currently in phase II clin. trials for the treatment of rheumatoid arthritis, osteoarthritis, and acute pain.

IT 415679-14-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of substituted benzenesulfonamides as selective cyclooxygenase-2 inhibitors from substituted benzyl bromides via coupling with acid chloride, conversion to  $\alpha$ -acetoxy ketones, cyclocondensation to form oxazoles and sulfonamidation)

RN 415679-14-0 HCAPLUS

CN Benzenesulfonamide, 2-fluoro-4-[2-methyl-4-(5-methyl-2-thienyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)

Me N S Me

h

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

FUII Text

ACCESSION NUMBER:

2002:72091 HCAPLUS

DOCUMENT NUMBER:

136:134566

TITLE:

Synthesis and use of heteroaryl-substitutedaryloxyalkylaryl compounds as  $\beta$ 3-adrenergic

agonists

INVENTOR(S):

Evers, Britta; Jesudason, Cynthia Darshini; Karanjawala, Rushad Eruch; Remick, David Michael; Ruehter, Gerd; Sall, Daniel Jon; Schotten, Theo; Siegel, Miles Goodman; Stenzel, Wolfgang; Stucky,

Russell Dean; Werner, John Arnold

PATENT ASSIGNEE(S):

Eli Lilly and Company, USA

SOURCE:

PCT Int. Appl., 96 pp.

DOCUMENT TYPE:

CODEN: PIXXD2 Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.								APPLICATION NO.						D	ATE		
		2002														2	0010	709
		w:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
			GM,	HR,	ΗU,	ID,	ΙL,	IN,	IS,	JP,	KE,	KG,	KΡ,	KR,	ΚZ,	LC,	LK,	LR,
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NO,	NZ,	PL,	PT,
			RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	TZ,	UA,	UG,	US,
			UΖ,	VN,	YU,	ZA,	ZW,	AM,	ΑZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM		
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	ΤZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,
			DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,
			ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG		
	AU	2001	0729	<u>17</u>		<b>A</b> 5		2002	0130		AU 2	001-	7291	7		2	0010	709
	EΡ	1303	509			A1		2003	0423		<u>EP 2</u>	001-	9521	25		2	0010	709
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	ΝL,	SE,	MC,	PT,
			ΙE,	SI,	LT,	LV,				•	AL,							
	BR	2001	0124	<u>09</u>		Α		2003	0722		BR 2	001-	1240	<u>9</u>		2	0010	709
		2004															0010	709
	<u>US</u>	2003	1911.								US 2	002-	3111	12		2	0021	213
		6730						2004										
		2003				A					NO 2						0030	
		2003				A1		2003	0430		<u>HR 2</u>						0030	113
PRIOR	(TI	APP	LN.	INFO	.:						US 2						0000	
											US 2	000-	<u> 2416</u>	14P		P 2	0001	019
											<u>US 2</u>						0010	
											<u>WO 2</u>	001-	US16	<u>519</u>	•	W 2	0010	709
OTHER	SC	SOURCE(S):					PAT	136:	1345	66								

GΙ

AΒ Title compds. I [A1-3 = C, N] provided that only one of A1-3 can be nitrogen; Het = (un)substituted, optionally benzofused 5 or 6 membered heterocyclic ring; R1,1a,1b = H, halo, OH, alkyl, alkoxy, haloalkyl, SO2-alkyl; R2 = H, alkyl; R3 = H alkyl; R4 = H, alkyl; or R3 and R4

<sup>\*</sup> STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

combine with the carbon to which both are attached to form a C3-C6 cyclic ring; or R4 and X1 combine with the carbon to which both are attached to form a C3-C8 cyclic ring; or R4 combines with X1, the carbon to which both are attached, and the Ph group to which X1 is attached to form a benzofused cycloalkyl radical; X is OCH2, SCH2, bond; X1 = bond, divalent hydrocarbon moiety; X2 = 0, S, NH, NHSO2, SO2NH, CH2, bond; X3 = (un)substituted Ph, 5 or 6 membered heterocyclic ring] were prepd. For instance, 2-(1-methylpyrazol-3-yl)phenol was reacted with (2S)-glycidyl 3-nitrobenzenesulfonate (THF, t-BuOK, reflux, 16 h) to give epoxide II. This was reacted with the amine derived from 4-(2-amino-2-methylpropyl)phenol and 2-chloro-3-cyanopyridine (alc. solvent,  $80^{\circ}\text{C}$ , 2-72 h) to give III. The intrinsic activity (Emax) of representative compds. of the invention was assessed relative to isoproterenol (a nonselective  $\beta3-\text{agonist}$ ); III had Emax = 55.0%. I are used in the treatment of diabetes, obesity, etc.

## IT 391922-26-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; synthesis and use of heteroaryl-substituted-aryloxyalkylaryl compds. as  $\beta 3\text{-adrenergic}$  agonists)

<u>391922-26-2</u> HCAPLUS

CN 2-Propanol, 1-[[2-[4-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl]-1,1-dimethylethyl]amino]-3-[2-(2-thienyl)phenoxy]-, (2S)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

RN

CRN <u>391922-25-1</u> CMF C30 H32 C1 N O5 S2

Absolute stereochemistry.

CM 2

 $\frac{76-05-1}{2}$  CMF  $\frac{76-05-1}{2}$  C2 H F3 O2

F = C = CO 2H

h

REFERENCE COUNT:

13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS

#### RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Section NUMBER :

ACCESSION NUMBER:

2000:637744 HCAPLUS

DOCUMENT NUMBER:

134:39080

TITLE:

A method for including protein flexibility in

protein-ligand docking: improving tools for database

mining and virtual screening

AUTHOR(S):

Broughton, H. B.

CORPORATE SOURCE:

Merck, Sharp & Dohme Neuroscience Research Centre,

Essex, UK

SOURCE:

Journal of Molecular Graphics & Modelling (2000),

18(3), 247-257

CODEN: JMGMFI; ISSN: 1093-3263

PUBLISHER:

Elsevier Science Inc.

DOCUMENT TYPE:

Journal English

LANGUAGE:

Second-generation methods for docking ligands into their biol. receptors, such as FLOG, provide for flexibility of the ligand but not of the receptor. Mol. dynamics based methods, such as free energy perturbation, account for flexibility, solvent effects, etc., but are very time consuming. We combined the use of statistical anal. of conformational samples from short-run protein mol. dynamics with grid-based docking protocols and demonstrated improved performance in two test cases. Our statistical anal. explores the importance of the av. strength of a potential interaction with the biol. target and optionally applies a weighting depending on the variability in the strength of the interaction seen during dynamics simulation. Using these methods, we improved the no. of known dihydrofolate reductase ligands found in the top-ranked 10% of a database of drug-like mols., in searches based on the three-dimensional structure of the protein. These methods are able to match the ability of manual docking to assess likely inactivity on steric grounds and indeed to rank order ligands from a homologous series of cyclooxygenase-2 inhibitors with good correlation to their true activity. Furthermore, these methods reduce the need for human intervention in setting up mol. docking expts.


IT 312611-71-5

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(method for including protein flexibility in protein-ligand docking - improving tools for database mining and virtual screening)

RN <u>312611-71-5</u> HCAPLUS

CN Thiophene, 3-[3-bromo-4-(methylsulfonyl)phenyl]-4-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full References

ACCESSION NUMBER:

1999:795808 HCAPLUS

DOCUMENT NUMBER:

132:35714

TITLE:

Preparation of heterocyclyl sulfonylbenzene compounds

as anti-inflammatory/analgesic agents.

INVENTOR(S):

Ando, Kazuo; Kato, Tomoki; Kawai, Akiyoshi; Nonomura,

Tomomi

PATENT ASSIGNEE(S):

Pfizer Pharmaceuticals Inc., USA

SOURCE:

PCT Int. Appl., 236 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

1: 1

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PAT	PATENT NO.			KIND DATE			APPLICATION NO.					D.	ATE					
WO	9964	415			A1	_	 1999	1216		WO 1.	999-	ІВ97	0		1	9990	531	
	w:	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,	
		DK,	EE,	ΕŚ,	FI,	GB,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IS,	JP,	ΚE,	KG,	
		ΚP,	KR,	KΖ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	MW,	MX,	
		NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	
		UA,	UG,	UZ,	VN,	YU,	ZW,	ΑM,	ΑZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM		
	RW:	GH,	GM,	KE,	LS,	MW,	SD,	SL,	SZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,	DK,	
		ES,	FΙ,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	ΝL,	PT,	SE,	BF,	ВJ,	CF,	CG,	
						,		MR,	,	,	•							
	AU 9938414									-								
	EP 1086097								EP 1	<u>999-</u>	<u>9210</u>	<u>43</u>		1	9990	531		
EP	1086							0519							,			
								FR,										FΙ
	2002									JP 2						9990		
	2671				E			0615		AT 1			_			9990		
	9903				A			0104		ZA 1								
	6294				В1		-	0925		US 1								
	2002		<u>54</u>		A1			0418		US 2	<u>001-</u>	8413	48		2	0010	424	
	6608				B2			0819		_					_			
	2003		64		A1			1204		US 2	003-	4657	<u>67</u>		2	0030	618	
	6727				В2		2004	0427				^ -	_					
ORITY	Y APP	LN.	INFO	.:						WO 1			_					
									٠.	WO 1			andrein .			9990		
										US 1						9991		
										<u>US 2</u>	<u> 001-</u>	8413	48		A3 2	0010	424	

OTHER SOURCE(S):

MARPAT 132:35714

GI

h

AΒ This invention provides a compd. of formula (I) or its pharmaceutically acceptable salt thereof [wherein A is partially unsatd. or unsatd. five membered heterocyclic, or partially unsatd. or unsatd. five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted Ph in formula I are attached to ring atoms of Ring A, which are adjacent to each other; R1 is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R1 is heteroaryl; R2 is C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkylamino, C1-4 dialkylamino or amino; R3, R4 and R5 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl or the like; or two of R3, R4 and R5 are taken together with atoms to which they are attached and form a 4-7 membered ring; R6 and R7 are independently hydrogen, halo, C1-4 alkyl-, halo-substituted C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino or N, N-di C1-4 alkylamino; and m and n are independently 1, 2, 3 or 4]. This invention also provides a pharmaceutical compn. useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens. This invention relates to compd. and pharmaceutical compns. for the treatment of cyclooxygenase mediated diseases. These compds. inhibit the biosynthesis of prostaglandins by intervention of the action of the enzyme cyclooxygenase on arachidonic acid, and are therefore useful in the treatment or alleviation of inflammation and other inflammation assocd. disorders, such as arthritis, in mammals (no data). Thus, To a stirred soln. of 1-[4-(Methylsulfonyl)phenyl]-5-(4-bromophenyl)-3trifluoromethyl-1H-pyrazole (0.27 g) in DME (8 mL) was added 3-thiophenboronic acid (0.09 g), bis(triphenylphosphine)palladium(II)chlor ide (0.05 g) and satd. NaHCO3 soln. (2 mL) at room temp. under nitrogen. The mixt. was heated at reflux temp. for 16 h, and cooled down to room temp. to give, after purifn. by flash chromatog. eluting with Et acetate/hexane (1/1), 1-[4-(Methylsulfonyl)phenyl]-5-[4-(2-thienyl)phenyl]-3-trifluoromethyl-1H-pyrazole (II) in 64 % yield.


#### IT 252559-81-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclyl sulfonylbenzene compds. as cyclooxygenase inhibitors, prostaglandin biosynthesis inhibitors, anti-inflammatory, and analgesic agents)

RN <u>252559-81-2</u> HCAPLUS

CN 1H-Pyrazole, 1-[3-fluoro-4-(methylsulfonyl)phenyl]-5-[4-(2-thienyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text

ACCESSION NUMBER:

1999:82258 HCAPLUS

DOCUMENT NUMBER:

130:210722

TITLE:

Synthesis and properties of novel aziridinyl azo dyes

from 2-aminothiophenes-Part 2: Application of some

disperse dyes to polyester fibers

AUTHOR (S):

Hallas, Geoffrey; Choi, Jae-Hong

CORPORATE SOURCE:

Dep. Colour Chemistry and Dyeing, Univ. Leeds, Leeds,

LS2 9JT, UK

SOURCE:

Dyes and Pigments (1998), Volume Date 1999, 40(2-3),

119-129

CODEN: DYPIDX; ISSN: 0143-7208

PUBLISHER:

Elsevier Science Ltd.

DOCUMENT TYPE:

Journal

LANGUAGE:

English

As series of yellow to greenish-blue aziridinyl azo dyes and their bromoethylamino azo precursors contg. a thienyl coupling moiety has been applied to conventional polyester fiber as well as microdenier polyester by high temp. exhaust dyeing. Heat transferability of these dyes onto polyester fiber has also been examd., using conventional heat-transfer printing techniques. The relevant dyeing characteristics, heat transferability, build-up, dyeability on microfiber polyester, washfastness, and lightfastness are given. These aziridinyl dyes are reactive to polyester fibers under HT dyeing conditions. Fabrics dyed with aziridinyl dyes re more resistant to solvent extn. than those dyed with conventional dyes. Residual liquors showed only a pale color when fabric dyed with aziridinyl dyes was dissolved and then pptd., whereas a colored polyester ppt. was obtained.

### IT 220964-99-8

RL: PRP (Properties); TEM (Technical or engineered material use); USES (Uses)

(brown dye; fastness to polyester under high-temp. exhaust dyeing and thermal-transfer printing conditions)

RN 220964-99-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[(2-bromoethyl)amino]-5-[[2-chloro-4-(methylsulfonyl)phenyl]azo]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{BrCH } 2\text{-CH } 2\text{-NH} \\ \text{Et0} - C \\ \end{array} \begin{array}{c} \text{S} \\ \text{Ph} \end{array}$$

REFERENCE COUNT:

21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text

ACCESSION NUMBER:

1999:82257 HCAPLUS

DOCUMENT NUMBER:

130:210776

TITLE:

Synthesis and properties of novel aziridinyl azo dyes from 2-aminothiophenes-Part 1: Synthesis and spectral

properties

AUTHOR(S):

Hallas, Geoffrey; Choi, Jae-Hong

CORPORATE SOURCE:

Department Colour Chemistry and Dyeing, Univ. Leeds,

Leeds, LS2 9JT, UK

SOURCE:

Dyes and Pigments (1998), Volume Date 1999, 40(2-3),

99-117

CODEN: DYPIDX; ISSN: 0143-7208

PUBLISHER:

Elsevier Science Ltd.

DOCUMENT TYPE:

Journal

LANGUAGE:

English

As series of yellow to greenish-blue aziridinyl azo dyes and their bromoethylamino azo precursors contg. a thienyl coupling moiety has been prepd. from 2-aminothiophenes. The 2-aminothiophenes were readily obtained by using the Gewald reaction. It was found that cyclization of the precursor dyes to the corresponding aziridine azo dyes brought about bathochromic shifts in absorption maxima. Further spectral comparisons with N-Ph azo dyes derived from other terminal 4-, 5-, 6-, 7-, and 8-membered cyclic groups showed that the N-thienylaziridinoazo dyes are relatively bathochromic. From the viewpoint of solvatochromism, a clear contrast existed between λmax values in different solvents; thus, a pos. solvatochromism was obsd. in aprotic solvents, whereas a hypsochromic shift was brought about in polar protic solvents. PPP-MO calcns. provided reliable predictions of absorption maxima for the various aziridinyl azo dyes and their precursor dyes.

IT 220964-99-8P

RL: RCT (Reactant); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(brown dye intermediate; prepn. of aziridinyl azo dyes from 2-aminothiophene coupling components)

RN <u>220964-99-8</u> HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[(2-bromoethyl)amino]-5-[[2-chloro-4-(methylsulfonyl)phenyl]azo]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

BrCH 
$$2$$
-CH  $2$ -NH  $S$ -N=N  $C1$ 

REFERENCE COUNT:

28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Zerenen es

ACCESSION NUMBER:

1997:421308 HCAPLUS

DOCUMENT NUMBER:

127:34521

TITLE:

Preparation of hydrazidyl, bis-hydrazidyl, and bis-aminomethyl carbonyl protease inhibitors

INVENTOR(S):

Carr, Thomas Joseph; Desjarlais, Renee Louise; Gallagher, Timothy Francis; Halbert, Stacie Marie; Oh,

Hye-Ja; Thompson, Scott Kevin; Veber, Daniel Frank;

Yamashita, Dennis Shinji; et al.

PATENT ASSIGNEE(S):

SOURCE:

USA

PCT Int. Appl., 253 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

Patent

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PAT	PATENT NO.				KIND DATE			APPLICATION NO.						D	ATE			
wo	9716	433					1997	0509		WO 1	996-	US18	000		1:	9961	030	
	W:	AL,	AM,	AU,	BB,	ВG,	BR,	CA,	CN,	CZ,	EE,	GE,	HU,	IL,	IS,	JP,	KG,	
		KP,	KR,	LK,	LR,	LT,	LV,	MD,	MG,	MK,	MN,	MX,	NO,	NΖ,	PL,	RO,	SG,	
		SI,	SK,	TR,	TT,	UA,	US,	US,	US,	US,	US,	US,	US,	US,	US,	US,	US,	
				•	AM,	•	•											
	RW:	KE,	LS,	MW,	SD,	SZ,	UG,	AT,	BE,	CH,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	
		ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	ML,	
		MR,	ΝE,	SN,	TD,													
ZA	9609	078			A											9961		
CA	2236	111			AA		19970509 <u>CA 1996-2236111</u>											
AU	9711	180		•	A1		1997	0522										
	1207				A													
BR	9612	344											_					
EP	9342								EP 1996-941981 GB, GR, IT, LI, LU, NL						19961030			
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	ΝL,	SE,	MC,	PT,	
			SI,	FI,														
NO	9801	<u>938</u>													_	9980		
	5998							1207		<u>US 1</u>						9990		
	6057						2000									9990		
	6232				В1		2001				•••••							
	6284				В1		2001											
	6331						2001			US 2						0000		
	2000					19980629 19980629				NO 2					_	0001		
	2000														20001229			
	2000														20001229			
	CN 1341590 A 2002032																	
CN	<u>CN 1341592</u> A 2002032						0327	CN 2001-104788						20010220				

CN 1341593 US 2002077455 US 6586466	A A1 B2	20020327 20020620 20030701	CN 2001-104789 US 2001-839410		20010220 20010420
US 2002173469 US 6562842	A1 B2	20021121 20030513	<u>US 2002-160314</u>		20020530
PRIORITY APPLN. INFO.:			US 1995-8108P	P	19951030
			US 1995-7473P	P	19951122
			US 1995-8992P	P	19951221
			US 1996-13747P	P	19960320
			US 1996-13748P	P	19960320
			US 1996-13764P	P	19960320
			US 1996-17455P	P	19960517
			US 1996-17892P	P	19960517
			US 1996-22047P	P	19960722
			US 1996-23494P	P	19960807
			WO 1996-US18000	W	19961030
			<u>US 1997-793915</u>	A3	19970214
			<u>US 1998-793915</u>	В3	19980430
			<u>US 1999-330284</u>	B1	19990611
		•	US 1999-330305	В1	19990611
			US 2000-633700	В1	20000807

OTHER SOURCE(S):

MARPAT 127:34521

Title compds. of formula D-CO-Q [D = CbzNHCH(Bu-i), Cbz-Leu-NHCH(Bu-i), 4-PhOC6H4SO2NHCH2, Cbz-Leu-NHNH, etc.; Q = NHCH(Bu-i) (2-carboxythiazol-4-yl), NHCH(Bu-i) (4-carboethoxythiazol-2-yl), NHNHCOCH(Bu-i)NHCbz, CH2NHSO2C6H4-4-OPh, etc.; Cbz = PhCH2O2C] and pharmaceutical compns. of such compds., which inhibit proteases, including cathepsin K (no data) were prepd. Such compds. are particularly useful for treating diseases of excessive bone loss or cartilage or matrix degrdn., e.g. osteoporosis, periodontitis, and arthritis. For example, Cbz-Leu-Leu-CH2Br was treated with H2NCSCO2Et in refluxing ethanol for 4 h to give Cbz-Leu-NHCH(Bu-i)(2-carboethoxythiazol-4-yl), which was sapond. by treatment with sodium hydroxide in THF to yield title compd. Cbz-Leu-NHCH(Bu-i)(2-carboxythiazol-4-yl).

### IT 190658-17-4P

CN

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of hydrazidyl, bis-hydrazidyl, and bis-aminomethyl carbonyl protease inhibitors)

RN <u>190658-17-4</u> HCAPLUS

4-Thiazolecarboxylic acid, 2-[3-[[(4-chlorophenyl)sulfonyl]methyl]-2-thienyl]-, 2-[(2S)-4-methyl-1-oxo-2-[[(4-pyridinylmethoxy)carbonyl]amino]pentyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\sum_{i-Bu}^{S} \sum_{i-Bu}^{N}$$

L6 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN



ACCESSION NUMBER:

1995:339482 HCAPLUS

DOCUMENT NUMBER:

122:105655

TITLE:

Preparation of 2-substituted-3,4-di(aryl)thiophene

cyclooxygenase inhibitors

INVENTOR(S):

Gauthier, Jacques Yves; Leblanc, Yves; Prasit,

Petpiboon

CODEN: PIXXD2

PATENT ASSIGNEE(S):

Merck Frosst Canada Inc., Can.

SOURCE:

PCT Int. Appl., 42 pp.

DOCUMENT TYPE:

Patent

LANGUAGE:

FAMILY ACC. NUM. COUNT:

English

PATENT INFORMATION:

PATEN	PATENT NO.					KIND DATE			APPLICATION NO.					D	ATE	
					-									-		
WO 942	26731			A1		1994	1124		WO 1	994-	CA26	4		1	9940	511
W	: AU,	BB,	BG,	BR,	BY,	CA,	CN,	CZ,	FI,	HU,	JP,	KR,	ΚZ,	LK,	LV,	MG,
	MN,	MW,	NO,	NZ,	PL,	RO,	RU,	SD,	SI,	SK,	TT,	UA,	US,	UZ		
RI	W: AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,
	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	ML,	MR,	NE,	SN,	TD,	TG		
<u>CA 21</u>	61789			AA		1994	1124		CA 1:	994-	2161	789		1	9940	511
<u>AU 94</u> 6	67184			A1		1994	1212		AU 1	994-	6718	4		1	9940	511
PRIORITY A	PPLN.	INFO	.:						US 1:	993-	6135	4	1	A 1	9930	513
									WO 1	994-	CA26	4	1	W 1	9940	511

OTHER SOURCE(S):

MARPAT 122:105655

GΙ

$$R^{1}$$

$$R^{2}$$

$$R^{4}$$


AΒ The title compds. [I; R1 = H, halogen, CN, NO2, CF3, C1-6 alkyl; R2 = C3-6 alkyl, (un) substituted Ph, (un) substituted heteroaryl; R3 = SO2CH3, S(O)(NH)CH3, SONH2, SO2NH2; R4 = H, halogen, CO2H, CF3], useful as cyclooxygenase inhibitors, are prepd. and I-contg. formulations claimed. Thus, 3-(4-fluorophenyl)-4-(4-sulfamoylphenyl) thiophene was prepd. and demonstrated 95% inhibition of PGE2 formation by osteosarcoma (143.98.2) cells at 100 nM.

## IT 160753-08-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (prepn. of 2-substituted-3,4-di(aryl)thiophene cyclooxygenase inhibitors)

RN 160753-08-2 HCAPLUS

Thiophene, 3-[3-bromo-4-(methylsulfonyl)phenyl]-4-(4-fluorophenyl)- (9CI) CN (CA INDEX NAME)



L6 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text serere

ACCESSION NUMBER:

1987:5016 HCAPLUS

DOCUMENT NUMBER:

106:5016

TITLE:

Thiazolylthiophene derivatives

INVENTOR(S):

Saeki, Sumi; Kawakita, Takeshi; Moriguchi, Akihiko;

Osuga, Kunio

PATENT ASSIGNEE(S):

Yoshitomi Pharmaceutical Industries, Ltd., Japan

SOURCE:

Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61118383	A2	19860605	JP 1984-237865	19841112
PRIORITY APPLN. INFO.:			JP 1984-237865	19841112
OTHER SOURCE(S):	CASREA	ACT 106:5016		

GΙ

h

The title compds. [I; R = Q; R1 = (substituted) amino; R2 = alkanoyl, CH2COR3 (R3 = OH, alkoxy, substituted amino), X = H, halo], useful as antiulcer agents, etc. (no data), were prepd. Thus, cyclocondensation of Q1COCH2Cl with (H2N)2CS in EtOH at 50° and acylation of the resulting I (R = Q1; R1 = NH2) with pivaloyl chloride in pyridine gave I (R = Q1; R1 = pivalamido).


## IT 105652-30-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of, as antiulcer agent)

RN 105652-30-0 HCAPLUS

CN Benzamide, N-[4-(5-acetyl-3-thienyl)-2-thiazolyl]-3-(aminosulfonyl)-4-chloro-(9CI) (CA INDEX NAME)



L6 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Paleis and

ACCESSION NUMBER:

1983:145034 HCAPLUS

DOCUMENT NUMBER:

98:145034

TITLE:

Thienylthiazole disazo disperse dyes

PATENT ASSIGNEE(S):

Mitsubishi Chemical Industries Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 57177060	A2	19821030	JP 1981-62070	19810424
JP 01034266	В4	19890718		
GB 2101623	A	19830119	GB 1982-11221	19820419
GB 2101623	B2	19840822		
DE 3215123	A1	19821209	DE 1982-3215123	19820423
DE 3215123	C2	19900308		
CH 647537	A	19850131	CH 1982-2539	19820426
US 4841036	A	19890620	US 1984-683323	19841218
PRIORITY APPLN. INFO.:			JP 1981-62070	19810424
			US 1982-372264	19820426

GΙ

$$\begin{array}{c|c}
R1 & & \\
RN = N & & \\
\end{array}$$

I (R = Ph, pyridyl, thiazolyl; R1 = H, Cl, Br, Ac; R2 = H, Cl, Br, Me, acylamino; R3 = H, Cl, Me, MeO, EtO; R4, R5 = H, alkyl, cyclohexyl, alkenyl, aryl) were prepd. and were used for dyeing polyester fibers in fast navy blue to green shades. I showed excellent stability to temp. and pH changes during dyeing. For example, aniline [62-53-3] was diazotized and coupled with 2-amino-4-(2-thienyl)thiazole [28989-50-6], and the 2-amino-5-(phenylazo)-4-(2-thienyl)thiazole [85242-87-1] obtained was diazotized and coupled with N-(2-acetoxyethyl)-N-ethylaniline [38954-40-4] to give I (R = Ph; R1 = R2 = R3 = H; R4 = Et; R5 = CH2CH2OAc) [85242-88-2], navy blue on polyester fiber.

#### IT 85242-65-5

RL: TEM (Technical or engineered material use); USES (Uses) (dye, for polyester fibers)

RN 85242-65-5 HCAPLUS

CN Propanenitrile, 3-[[4-[[5-[[2-chloro-4-(methylsulfonyl)phenyl]azo]-4-(2-thienyl)-2-thiazolyl]azo]phenyl]ethylamino]- (9CI) (CA INDEX NAME)

=> file caold COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 74.92 231.81 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -10.29-10.29

FILE 'CAOLD' ENTERED AT 10:58:25 ON 09 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter  $\underline{\text{HELP FIRST}}$  for more information.

eb

## => d his

h

(FILE 'HOME' ENTERED AT 10:54:43 ON 09 AUG 2004)

FILE 'REGISTRY' ENTERED AT 10:54:48 ON 09 AUG 2004

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 41 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 10:57:16 ON 09 AUG 2004

L4 14 S L3

L5 2 S L4 AND BROWN, D?/AU